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Cost to patients of obtaining treatment for HIV/AIDS in 
South Africa 
Sydney Rosen, Mpefe Ketlhapile, Ian Sanne, Mary Bachman DeSilva 
Background. South Africa is providing antiretroviral (ARV) 
drugs for HIV I AIDS free of charge in order to increase 
access for poorer patients and promote adherence. However, 
non-drug costs of obtaining treatment may limit access. 
We estimated the costs that South African patients incur in 
obtaining antiretroviral therapy (ART). 
Methods. A random sample of adult pre-ART and ART patients 
attending a public urban hospital (site 1), a peri-urban 
(informal settlement) non-governmental organisation (NGO) 
clinic (site 2), and a rural NGO clinic (site 3) were interviewed 
during a routine clinic visit. Mean and median costs were 
calculated for each site. 
Results. Ninety-one per cent of subjects paid for transport to 
attend the clinic. The median cost was modest (R10- R28), but 
patients in the top decile at sites 1 and 3 paid RSO or more. 
Mean transport costs were substantially higher at site 1 (R75) 
than at site 2 (R18) or Site 3 (R47). Site 1 waived its R45 visit 
In late 2003, the South African National Department of Health 
announced its Operational Plan for Comprehensive HIV and 
AIDS Care, Management and Treatment for South Africa.1 The 
plan included provision of antiretroviral therapy (ART) free 
of charge at public health care facilities to medically eligible 
patients, with the goal of making effective AIDS care and 
treatment accessible to the large majority of the population not 
able to afford private medical care. By September 2006, some 
235 000 adult South Africans were receiving ART from public 
health care facilities, along with roughly 80 000 treated in the 
non-governmental organisation (NGO) and private sectors.2 
Although patients at public clinics and many NGO clinics 
do not have to pay for antiretroviral (ARV) drugs, it is widely 
understood that treatment is not 'free'. Patients bear the costs 
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fee for most subjects, but more than 80% of subjects at sites 
2 and 3 paid fees of R30 and R70, respectively. Few subjects 
at any site paid for substitute labour (7%) or suffered income 
loss (12%) during the visit. In the previous week, 60% of all 
subjects purchased non-prescription medicines or special 
foods, at a median cost of R81, R45 and RSO for sites 1, 2 and 
3, respectively. The upper quartile of patients paid more than 
R150 for these purchases. Twelve per cent of patients reported 
paying for other medical care in the previous week, while 48% 
said that they had utilised caretakers' time. 
Conclusions. Patients must visit a treatment clinic at least 6 
times in the year in which they start ART. The average cost 
per visit is R120, plus travel and waiting time. Patients and 
caregivers also spend considerable time and money between 
visits. Patient costs should be considered in efforts to sustain 
adherence and expand access. 
S Afr Med] 2007; 97: 524-529. 
of transport to and from the clinic and the opportunity costs 
of the time required for frequent clinic visits. Although ARVs 
themselves are free of charge, many clinics charge a visit fee 
and/ or expect patients to pay for supplemental drugs needed 
as part of their treatment. In addition, patients are often 
persuaded by caregivers, pharmacies, traditional healers and 
commercial advertisers to purchase high-quality foods and a 
wide range of legitimate and illegitimate products and services 
claiming to improve their health while on ART. 
Throughout the world, both the fee and non-fee costs of 
obtaining medical care have been found to limit access to acute 
care and adherence to chronic care.3'4 In African countries, 
charging fees for ARVs has repeatedly been associated with 
high rates of loss to follow-up and mortality. 5 7 In Ethiopia, 
for example, travel time, travel distance, and transport and 
accommodation costs were found to be major barriers to 
accessing eye care services8 and completing tuberculosis 
treatment9 and reduced the use of clinic and hospital services 
among poor people in Cote d'Ivoire.10 Research in Malawi 
identified transport costs as a barrier to initial uptake of 
ART, as well as to adherence.n However to the best of our 
knowledge only one previous study of the non-fee costs to 
patients of enrolment in ART programmes has been conducted 
in South Africa, and it included only public sector sites in a 
single province.12 
In view of the evidence that cost is an important barrier 
to accessing medical care and to ART uptake and adherence, 
it is useful to know how much South African patients are 
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spending on their care. In this article we self-reported 
expenditure data from a cohort of adult patients enrolled 
in public and NGO treatment programmes in Gauteng and 
Mpumalanga. 
Methods 
The data presented here are drawn from a longitudinal 
study of the social and economic outcomes of HIV I AIDS 
treatment conducted at three treatment sites. The sites are 
described in Table I. Site l, the Themba Lethu Clinic, is the 
HIV clinic of Helen Joseph Hospital, a large, urban public 
hospital in Gauteng Province under the Gauteng Department 
of Health. Site 2, the Witkoppen Health and Welfare Centre, 
is also in Gauteng and is a non-governmental and Gauteng 
DoH primary care clinic mainly serving an area of informal 
settlements outside Johannesburg. Site 3, the ACTS Clinic, is a 
non-governmental HIV I AIDS clinic that serves a largely rural 
population in Mpumalanga province. Site 1 is funded primarily 
by the provincial government, site 2 by a combination of 
donors and the provincial government, and site 3 by donors. 
All three sites provide ARV drugs to patients free of charge, 
though a clinic visit fee was charged during the study period to 
those able to pay. 
Between July 2005 and June 2006, a random sample of adult 
patients receiving ART or pre-ART care at the 
were enrolled in the study. Patients who were 
study included all those receiving pre-ART care and those 
who had initiated ART less than 6 months before recruitment. 
The baseline questionnaire, which was administered during 
subjects' routine clinic visits, included detailed questions on the 
costs incurred to visit the clinic on that day and money 
spent on health-related purchases in the week preceding the 
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visit. Mean and median costs and interquartile ranges were 
then calculated for each site. 
Results 
Study sites and participants are described in Table I. A total 
of 1 072 subjects were enrolled in the cohort and provided 
baseline data. As Table I indicates, 56% of the sample was 
drawn from site 1, 29% from site 2, and 15% from site 3. Across 
all the sites, most subjects (79%) were female, with a weighted 
average age of 34 years. Fewer than half of the subjects 
reported being employed, either formally or informally, at the 
time of the baseline interview. 
Table II reports on transport mode and travel time and 
the mean and median costs incnrred by study subjects for (i) 
transport; (ii) clinic fees; (iii) payment of substitute labour; 
(iv) income loss on the day of the clinic visit; (v) purchase 
of special foods and medicines and medical care provided 
outside the study clinic in the week preceding the visit; and 
(vi) caretaker time required in the past week. As is the case 
with many cost data, the distribution of costs in our study was 
highly skewed, with most subjects paying relatively modest 
amounts but a few subjects paying very large amounts. For 
such data, it is recommended that as much detail as possible 
be provided on the distributionY For each site and cost item, 
therefore, we included the overall sample mean and the mean, 
median, interquartile range, and top decile costs for subjects 
who incurred a cost for that item (Table ll). Figs la - c further 
illustrate the distribution of transport costs, total costs per 
visit, and costs for special foods and medications for the entire 
Almost all subjects used minibus taxis or buses for the 
to the clinic. Median round trip travel time ranged from 1 hour 
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Table II. Costs incurred by study subjects (value in 2005 rands unless otherwise noted) 
Site 2 . 
Site 1 (infonnal Site3 
(urban hospital) sE.>ttlemt?nt clinic) (rural clinic) All 
No. of respondents 606" 310t 156t 1072 
Costs incurred for today's visit 
Transport mode (%) 
Minibus taxi or bus 81 87 81 83 
Private car 14 8 15 12 
Walked 3 5 1 3 
Other 3 0 3 2 
Travel time (minutes, round trip) 
Overall mean(SD) 119 (88) 79 (83) 158 (88) 113 (90) 
Median (IQR) 120 (60- 160) 60 (40- 90) 180 (78 188) 90(60 155) 
Top decile (90th percentile) 240 120 300 240 
Transport cost (round trip) 
Overall mean (SD) 75 (317) 18 (70) 47 (83) 55 (245) 
%paying> RO 90 91 95 91 
For those paying > RO 
Mean (SD) 84 (333) 20 (74) 50 {84) 60 (256) 
Median (IQR) 20 (10- 29) 10 (10- 15) 28 (14- 39) 18 (10 28) 
Top decile 50 24 90 50 
Clinic fee 
Overall mean (SD) 11 (19) 23 (22) 66 (21) 22 (27) 
% >RO 26 81 94 52 
For paying> RO 
Mean (SD) 42 (6) 28 {21) 71 (10} 43 (23) 
Median (IQR) 45 (35- 45) 30 (30- 30) 70 (70- 70) 35 (30 -70) 
Top decile 45 30 70 70 
Payment for substitute labour§ 
Overall mean (SD) 4 (18} 2 (22) 10 (87) 4 (38) 
%paying> RO 6 4 13 7 
For those paying > RO 
Mean (SO) 60 (46) 76 (101) 77(237) 67 (136) 
Median (IQR) 50 (40 60) 38 (21 - 83) 20 (10- 23) 40 (20- 60) 
Top decile 120 225 75 100 
Loss of income 
Overall mean (SD) 13 (70) 24 (::,!03) 1 (8) 14 (121) 
% paying > RO 12 4 12 
For those paying > RO 
Mean (SD) 149 (187) 177 (536) 69 (44) 159 (373) 
Median (IQR) 100 (53 -150) 90 (60- 100} 69 (54 85) 90 (50 135) 
Top decile 200 150 100 200 
Total cost of visit 
Overall mean (SD) 104 (327) 67 (218) 124 (122) 96 (277) 
%paying >RO 94 97 97 95 
For those paying > RO 
Mean(SD) 111 (337) 69 (221) 128 (122) 101 (283) 
Median (IQR) 30 (17- 65) 40 (30- 50) 98 (84 -122) 40 (22- 88) 
Top decile 150 125 174 142 
Costs incurred in previous week 
Purchase of special foods or medicines 
for own use 
ml Overall mean (SD) 100 (299) 174 (754) 54 (89) 115 (464) 
%paying> RO 61 60 57 60 
For those paying > RO 
Mean (SD) 164 (368) 293 (961) 94 (101) 191 (587) 
Median (IQR) 81 (30- 160) 45 (20 129) 50 (30 -100) 60 (27 150) 
decile 300 300 250 300 
July 2007, Vol. 97, No. 7 SAMJ 
ORIGINAL ARTICLES 
Table II. Costs incurred by study subjects (value in 2005 rands unless otherwise noted) (continued) 
Site 2 
Site 1 (informal Site 3 
(urban hospital) settlement clinic) (rural clinic) All 
Payment for other medical care 'II 
Overall mean (SD) 14 (75) 12 (51) 39 (74) 17(70) 
%paying> RO 11 9 28 13 
For those paying >RO 
Mean (50) 125 (196) 135 (118) 141 (72) 132 (151) 
Median (IQR) 69 (35 -119) 110 (45- 180) 150 (100 200) 100 (45- 160) 
Top decile 250 278 200 240 
Caretaker's time in previous week (hours) 11 
Overall mean (SO) 2.6 (4.8) 2.3 (8.4) 2.9 (3.0) 2.6 (5.9) 
%using any caretaker time 49 37 63 48 
For those using any caretaker time 
Mean (SD) 5.3 (5.7) 6.2 (12.9) 4.7 (2.4) 5.4 (7.6) 
Median (lQR) 5.0 (2- 5) 2.5 (2- 5) 5.0 (3- 5) 5.0 (2- 5) 
Top decile 10.0 10.0 8.0 10.0 
loss of income and payment for other medical care, N ~ 603; 
clinic fee and payment for other medical care, No:::: 309; for 
foods or medicines for own use, N;;;:;; 604. 
~ 308; [or loss of income, N ~ 306; for purchase of special foods or medicines for own usc, N ~ 305. 
145. 
'Did you have to p.:1y anyone to take over your tasks while you are at the clinic/ including payment for child care?' 
on anv othC:'r 111cdical care (formal or traditional) 
pcrsot; (person who takes care of you or 
at site 2 to 3 hours at site 3; the top decile of subjects travelled 
for more than 4 hours. For the 91% of subjects who paid for 
transport, there was a similar distribution of median transport 
costs - lowest for site 2 and highest for site 3. This is not 
surprising, given the location of the three sites and associated 
patient catchment areas. Site 2 draws most of its patients from 
nearby informal settlements, while site 3, situated in a rural 
area, attracts from a much larger region. Site 1, in a 
major urban centre, serves both urban and township residential 
areas at distances. 
Perhaps less expected is the finding that for the majority of 
~LU/f~'-'"' transport costs were fairly modest, under 
R40 per round trip through the 75th percentile at all three sites. 
Only among the 10% of subjects who paid the amounts 
for transport did costs exceed RSO, to the highly 
skewed distribution shown in Fig. la. A separate analysis 
(not shown) found very little relationship between travel time 
and transport cost; almost none of those who paid more than 
R100 for transport reported a round trip travel time greater 
than 3 hours. Clinic staff noted that families of patients who 
incurred high transport costs had usually rented a private car 
for the trip, owing either to lack of public transportation or the 
patient's condition. 
Patients' costs for clinic fees depended almost entirely on 
the policies of the individual clinics. The public hospital, site 
1, had a standard fee of R45 per visit but waived this fee for 
nearly three-quarters of the study sample, based on patient 
ability to pay. Fees at this site have since been eliminated 
completely. Most subjects obtaining care at the two NGO sites 
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did pay the clinic fee, which was set at R30 at site 2 and R70 at 
site 3. Both sites subsidised or waived this fee for the poorest of 
their patients. The role of the fee in clinic attendance 
cannot be explored in this study, as data were collected only 
from patients who did attend, at least on the date of the 
baseline interview. The rural clinic (site 3), where the visit fee 
of R70 could be expected to pose a barrier to many patients, is 
located roughly 20 km from a public ARV rollout site at which 
no fee is charged. Possible explanations for patients' preference 
for the NGO clinic may be its location, shorter waiting times, 
facility appearance, and/or reputation for quality. 
Few subjects reported paying for substitute labour while 
they visited the clinic (4 13%) or losing anything from their 
salaries or wages because of the time spent at the clinic (4 
16%). Most subjects were not employed at the time of the 
interview; for those who were, employment regulations in 
South Africa require that all employees have access to paid sick 
leave, reducing the income loss that patients might otherwise 
incur. Income loss was most common at site 2, where 
many patients work informally and are for work 
performed. 
When all of the costs associated with the clinic visit 
(transport, fee, substitute labour, and income loss) are 
combined, only 5% of subjects in the full sample reported that 
they did not incur any costs. The average total cost per visit 
was R96 across the entire the distribution, as shown in 
Fig. lb, was highly skewed, with a median of R40 among those 
paying more than RO. 
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Distribution of most frequently incurred costs for the entire sample 
lrn1Nr>nrl costs (round trip); b- total cost per clinic visit; c ·····special 
medications). 
Perhaps the most surprising finding in this study is the 
large amounts of money subjects reported spending on special 
foods and medications in the week preceding the interview. 
Approximately 60% of subjects reported making such 
purchases in the preceding week, and the median amounts 
spent by those who did, viz. R45- R81, exceeded costs for 
transport and clinic fees. As illustrated in Fig. lc, enough 
subjects spent very large amounts (more than R100) to generate 
an overall average for the entire sample of R114/subject. The 
content of these purchases is not clear, but interviewers were 
instructed to ask only about items that subjects purchased 
specifically to improve their own health, not general purchases 
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or purchases made for others. Interviewers reported that fruit 
and vegetables, vitamins, herbal remedies, non-prescription 
'immune boosters', and various non-prescription substances 
claiming to have anti~ AIDS properties were the most common 
items mentioned. 
Also unexpectedly, only 13% of subjects reported spending 
any money on medical care obtained outside the study 
clinic in the previous week, although those who did spent 
large amounts, with a median ranging from R69 to R150. 
Although the question explicitly included payments made to 
traditional healers, interviewers guessed that many subjects 
were unwilling to disclose such payments in the belief that 
use of traditional healing would meet with disapproval. The 
interviewers speculated that tht~ majority of subjects 
consulted traditional healers in addition to attending the clinic. 
Finally, approximately half the sample said that other people 
had spent time taking care of them or helping them vvith their 
tasks in the previous week. Those 1vho utilised caretaker time 
in the previous week did so for a median of 5 hours. 
Discussion 
Although ARV medications are provided at no to 
patients at public facilities and many NGO facilities in South 
Africa, AIDS treatment is 'free' for only a handful of those 
on ART. We found that 95% of a random sample of patients 
in care at one public and two NGO sites in Gauteng and 
Mpumalanga incurred costs on the day of their clinic visit, 
and half faced a cost of more than R40 per visit. Transport 
was the only cost incurred by nearly two-thirds of subjects 
at site 1, the public hospital; at sites 2 and 3, most subjects 
paid for both transport and visit fees. Across all three sites, a 
majority of subjects reported spending money on special foods 
and medicines in the previous week, and the amounts spent 
were with a median of R60 for the 60% who made such 
purchases. 
Distribution was highly skewed for all types of costs 
incurred by study subjects. At the lower end of the 
distribution, subjects at site 1 for whom the clinic fee was 
waived and whose only other cost was transport spent a 
median of just R20 per visit. At the upper end, subjects at site 
3 who paid for both transport and clinic fees spent a median 
of R98 per visit. In general, each site included some subjects 
who paid surprisingly large amounts for transport and for 
purchases of foods and medicines, suggesting that for a 
small fraction of patients, there is both ability and willingness 
to pay for medical care when necessary. On the other hand, the 
costs incurred by even the 25% of subjects who spent the least 
make it likely that cost is deterring many eligible patients from 
enrolling or remaining in treatment programmes. 
The transport costs and rates of income loss presented here 
can be compared with those from two other studies relevant to 
South Africa, one from the Western Cape12 and the other from 
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Table III. Comparison of results with other patient cost estimates 
Cost Western Cape Botswanat This study 
Study sites 5 public hospitals and clinics 4 public district hospitals 1 public hospital, 2 NGO clinics 
% of sample paying 
for transport 64% NA 91% 
Transport cost (full sample) R3 (mean) R13 (median) RSS (mean) 
Lost income because 
of clinic visit(% of sample) 6% 29% 12% 
Source (Pienaar eta/. 12) (Kgatlwane et a/.14 ) This study 
"calculated by authors from data provided. 
tValues shown reflect an exchange rate of Pula 1.3/I~and 1.0, the average rate during the period of data collection. 
NA ::::: data not available. 
neighbouring Botswana/' as shown in Table III. Compared 
with the Western Cape study, which included many subjects 
who walked to the clinic, subjects in our study were more 
likely to pay for transport, and the amounts our subjects 
reported paying far exceeded those recorded for the Western 
Cape and Botswana samples. A minority of subjects in all 
studies suffered a loss of income because of the clinic visit, 
presumably reflecting the low employment rates in the study 
populations, as well as the role of paid sick leave in smoothing 
income flows. 
South African patients who become eligible for ART under 
national treatment guidelines can expect to make at least 6, 
and sometimes as many as 10, clinic visits in their first year 
on treatment, including pre-ART preparation visits and post-
initiation monitoring and medication pick-up visits. For those 
in the upper half of our cost distribution, for whom the total 
cost per visit exceed R40, the amounts of money required to 
initiate and adhere to therapy in the first year are substantial. 
Whether they are prohibitive, such that some patients are 
discontinuing or interrupting treatment due to cost while 
others never start at all, is unknown. However, as the national 
treatment programme expands further into peri-urban and 
rural communities it should be anticipated that costs to 
patients will be a barrier to universal access. 
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